Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical Schoo...
Guardado en:
Autores principales: | Singer MA, Cohen SR, Groth SL, Porbandarwalla S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/da4a9277206a42c9bea4f22a7cc3547e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane PA, et al.
Publicado: (2011) -
Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
por: Eltutar K, et al.
Publicado: (2013) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017) -
Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan R, et al.
Publicado: (2016)